<code id='AF3B212701'></code><style id='AF3B212701'></style>
    • <acronym id='AF3B212701'></acronym>
      <center id='AF3B212701'><center id='AF3B212701'><tfoot id='AF3B212701'></tfoot></center><abbr id='AF3B212701'><dir id='AF3B212701'><tfoot id='AF3B212701'></tfoot><noframes id='AF3B212701'>

    • <optgroup id='AF3B212701'><strike id='AF3B212701'><sup id='AF3B212701'></sup></strike><code id='AF3B212701'></code></optgroup>
        1. <b id='AF3B212701'><label id='AF3B212701'><select id='AF3B212701'><dt id='AF3B212701'><span id='AF3B212701'></span></dt></select></label></b><u id='AF3B212701'></u>
          <i id='AF3B212701'><strike id='AF3B212701'><tt id='AF3B212701'><pre id='AF3B212701'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:knowledge    - browse:1355
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus